Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorNakhia Impex LLC

About this trial

This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel for ultra-rapid relief of moderate-to-severe skin pruritus from diverse etiologies (eczema, neurodermatitis, insect bites, urticaria, postoperative wound itch). Eligible participants will receive a single topical application of HA35 gel. The primary objective is to assess pruritus relief at 10 seconds, 45 minutes, 8 hours, 12 hours, and 24 hours post-application. Safety and local skin tolerability will be evaluated throughout the observation period. This is a minimal-risk, non-pharmacological, non-invasive intervention.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18-65 years, male or female

Moderate-to-severe skin pruritus (NRS ≥6) due to eczema, neurodermatitis, insect bites, urticaria, or postoperative wound itch

Able to understand and complete NRS assessments independently

Signed written informed consent

Disqualifiers

Topical corticosteroid/antihistamine use within 2 weeks

Infected, broken, or exudative skin lesions at the application site

Known hypersensitivity to hyaluronan or gel components

Severe systemic disease or immune dysfunction

Trial design

Design model

Single group

Treatments tested in this trial

  • 10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Anti-Pruritic Gel

    Device

    Topical skin gel containing 10% high-concentration 35 kDa hyaluronan fragment. Applied topically to pruritic areas to provide ultra-rapid relief of skin itching and improve associated inflammatory signs.

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: HA35 Topical Gel Intervention GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in Skin Pruritus NRS Score (0-10)

Change in pruritus intensity measured by 0-10 NRS, 0 = no itching, 10 = worst imaginable itching.

Time frame
Baseline to 10 seconds, 45 minutes, 8 hours, 12 hours, and 24 hours after application

Secondary outcomes

1

Onset time of clinically significant pruritus relief

Time frame
Within 10 seconds after application
2

Duration of pruritus relief

Time frame
Up to 24 hours
3

Change in Skin Erythema Severity (0-10 NRS Score)

Change in skin erythema severity at the application site, assessed using a 0-10 Numeric Rating Scale (NRS), where 0 = no erythema and 10 = maximum redness.

Time frame
Baseline to 45 minutes and 24 hours after application
4

Change in Local Skin Swelling Severity (0-10 NRS Score)

Change in local skin swelling severity at the application site, assessed using a 0-10 Numeric Rating Scale (NRS), where 0 = no swelling and 10 = maximum swelling.

Time frame
Baseline to 45 minutes and 24 hours after application

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: